Opiate Substitution Treatment
"Opiate Substitution Treatment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Medical treatment for opioid dependence using a substitute opiate such as METHADONE or BUPRENORPHINE.
| Descriptor ID |
D058850
|
| MeSH Number(s) |
E02.319.620
|
| Concept/Terms |
Opiate Substitution Treatment- Opiate Substitution Treatment
- Opiate Substitution Treatments
- Substitution Treatment, Opiate
- Substitution Treatments, Opiate
- Treatment, Opiate Substitution
- Treatments, Opiate Substitution
- Opioid Substitution Treatment
- Opioid Substitution Treatments
- Substitution Treatment, Opioid
- Substitution Treatments, Opioid
- Treatment, Opioid Substitution
- Treatments, Opioid Substitution
- Opioid Substitution Therapy
- Opioid Substitution Therapies
- Substitution Therapies, Opioid
- Substitution Therapy, Opioid
- Therapies, Opioid Substitution
- Therapy, Opioid Substitution
- Opiate Replacement Therapy
- Opiate Replacement Therapies
- Replacement Therapies, Opiate
- Replacement Therapy, Opiate
- Therapies, Opiate Replacement
- Therapy, Opiate Replacement
- Opioid Replacement Therapy
- Opioid Replacement Therapies
- Replacement Therapies, Opioid
- Replacement Therapy, Opioid
- Therapies, Opioid Replacement
- Therapy, Opioid Replacement
|
Below are MeSH descriptors whose meaning is more general than "Opiate Substitution Treatment".
Below are MeSH descriptors whose meaning is more specific than "Opiate Substitution Treatment".
This graph shows the total number of publications written about "Opiate Substitution Treatment" by people in this website by year, and whether "Opiate Substitution Treatment" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 6 | 1 | 7 |
| 2013 | 3 | 1 | 4 |
| 2014 | 5 | 1 | 6 |
| 2015 | 9 | 0 | 9 |
| 2016 | 6 | 2 | 8 |
| 2017 | 6 | 3 | 9 |
| 2018 | 6 | 2 | 8 |
| 2019 | 5 | 3 | 8 |
| 2020 | 3 | 5 | 8 |
| 2021 | 1 | 8 | 9 |
| 2022 | 0 | 17 | 17 |
| 2023 | 0 | 10 | 10 |
| 2024 | 14 | 7 | 21 |
| 2025 | 12 | 4 | 16 |
| 2026 | 9 | 1 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Opiate Substitution Treatment" by people in Profiles.
-
Ameral V, Falcón AK, Wolkowicz NR, Patterson JA, MacLean RR. Psychiatric Comorbidity in Research on Medications for Opioid Use Disorder: A Systematic Review. J Nerv Ment Dis. 2026 Sep-Oct 01; 214(5):97-116.
-
Martin R, Carpenter R, Hoadley A, Bailey A, Kang A, Rich J, Rohsenow D, Hurley L, Clarke J. Population-level benefits of correctional medications for opioid use disorder. J Subst Use Addict Treat. 2026 Dec; 191:210111.
-
Bailey A, Hughto JMW, Kelly PJA, Dunsiger SI, Martin RA. Patient preferences for medications to treat opioid use disorder in carceral settings: Implications for tailored implementation and service delivery. J Subst Use Addict Treat. 2026 Dec; 191:210099.
-
Bailey A, Kang AW, Glenn VP, Tavares T, Adams J, McNiff L, Hurley L, Martin RA. How mobile units are shaping opioid treatment experiences: Insights from patients of mobile and traditional opioid treatment programs. J Subst Use Addict Treat. 2026 Dec; 191:210100.
-
Monico LB, Bambury EA, Foreman JK, Avila M, Martin SA. Retention in Telehealth-Delivered Buprenorphine Treatment for Opioid Use Disorder: Multistate Retrospective Cohort Study. J Med Internet Res. 2026 08 14; 28:e100527.
-
Hsu HE, Lodi S, Yan S, Bovell-Ammon BJ, Christine PJ, Tilhou AS, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR. Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment. JAMA Netw Open. 2026 07 01; 9(7):e2623280.
-
Bailey A, Kang AW, Martin RA. Advancing Opioid Use Disorder Treatment: A Narrative Review of Evidence-Based Solutions to Systems-Level Barriers in the US. Subst Use Addctn J. 2026 Oct; 47(4):1244-1256.
-
Stopka TJ, Rottapel RE, Ruggiro M, Santelices C, Friedmann PD, Pivovarova E, Evans EA. "So what's gonna happen when I get out of here?" Qualitative barriers and facilitators to MOUD continuity post-release from jail. Drug Alcohol Depend. 2026 Aug 01; 285:113227.
-
Votaw VR, Rosen RL, Peckham AD, London Z, Philpotts LL, Weiss RD, McHugh RK, Streck JM. Investigating the Effects of Buprenorphine Treatment on Depression Symptoms Among Adults with Opioid Use Disorder: A Scoping Review. J Dual Diagn. 2026 Apr; 22(2):158-190.
-
Schoenfeld EM, Soares WE, Girardin AL, Simon C, Strokes N, Lauren N, Santana CS, Beck SA, Westafer LM. "Talk About It!" Shared Decision-Making for Methadone and Buprenorphine Initiation: Development and Preliminary Evaluation of a Conversation Aid via Community-Based Participatory Research. Acad Emerg Med. 2026 03; 33(3):e70256.